IDEAYA Biosciences, Inc. (IDYA) Fair Value 2026

IDYA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.9 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (13/100)

Quick Summary — As of 2026-08-27, IDEAYA Biosciences, Inc. (IDYA) trades at $41.77. QOC: 6.9/10. Value Trap Risk: 13/100 (SAFE). 0/13 models active.

Key Facts

Ticker
IDYA
Price
$41.77
Quality Score
6.9/10
Value Trap Risk
13/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give IDYA?

0 Intrinsic Value Models vs. Current Price ($41.77)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is IDEAYA Biosciences, Inc. (IDYA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, IDEAYA Biosciences, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About IDYA?

0 of 13 models are currently active for IDYA. See which stocks rank higher →

How Does IDYA Rank in Biotechnology?

Among 620 Biotechnology stocks, IDYA ranks #52 by Quality of Company score. CirclFi's QOC score of 6.9/10 evaluates 32 fundamental signals. A score of 6.9 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, IDEAYA Biosciences, Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating IDYA should weigh these sector-specific dynamics alongside our model-derived fair values.

Is IDYA a Value Trap?

CirclFi's Value Trap algorithm assigns IDYA a score of 13/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for IDEAYA Biosciences, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, IDEAYA Biosciences, Inc.'s fundamental quality profile registers 6.9/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every IDYA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy IDEAYA Biosciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

GMABGenmab A/SQOC 6.9NRIXNurix Therapeutics, Inc.QOC 6.9ADAGAdagene Inc.QOC 7.0FHTXFoghorn Therapeutics Inc.QOC 6.9PRTAProthena Corporation plcQOC 7.0LCTXLineage Cell Therapeutics, Inc.QOC 6.9DNTHDianthus Therapeutics, Inc.QOC 5.6DMRADamora Therapeutics, Inc.QOC 4.8GRIGRI Bio, Inc.QOC 4.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: GMAB · NRIX · ADAG · FHTX · PRTA · LCTX · DNTH · DMRA · GRI · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to IDYA?

7 companies across all industries closest to IDYA’s Quality of Company score of 6.9/10.

STSensata Technologies Holding plcQOC 6.9TXTernium S.A.QOC 6.9LYBLyondellBasell Industries N.V.QOC 6.9CERSCerus CorporationQOC 6.9DFHDream Finders Homes, Inc.QOC 6.9CEPLCapstone Energy+, Inc.QOC 6.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ST · TX · LYB · CERS · DFH · CEPL · NVDA

Where Does IDYA Sit in CirclFi's Biotechnology Rankings?

IDYA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About IDEAYA Biosciences, Inc.’s Valuation?

What is IDEAYA Biosciences, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for IDEAYA Biosciences, Inc. (IDYA). The Quality of Company score is 6.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is IDYA overvalued or undervalued right now?

At $41.77, 0 of 0 active models suggest IDYA may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits IDEAYA Biosciences, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.9 mean for IDYA?

IDEAYA Biosciences, Inc.'s QOC of 6.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on IDYA?

CirclFi analyzes IDYA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is IDYA a value trap in 2026?

IDEAYA Biosciences, Inc.'s Value Trap score is 13/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns IDEAYA Biosciences, Inc. (IDYA) a Quality of Company score of 6.9/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/IDYA/ · Methodology
Primary sources for this IDYA valuation
  • Financial statements: IDEAYA Biosciences, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001676725) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for IDYA as of ; valuations recomputed .